Resolving Source Ambiguity in Circulating Biomarkers

23 concepts18 papers

When a biomarker is detected in a systemic biofluid like blood or urine, it is tempting to treat it as a direct window into a specific disease site. However, biofluids are fundamentally pooled reservoirs. Molecules secreted by a damaged neuron, a malignant cell, or an inflamed kidney mix instantly with the background output of every other organ system in the body.

This creates a profound problem of source ambiguity: a systemic signal lacks spatial and cellular resolution. To build reliable liquid biopsies, researchers must find ways to trace these mixed signals back to their precise cellular and tissue origins.

The Spatial Blind Spot: Central vs. Peripheral

The challenge of source ambiguity is particularly acute in neurological and systemic conditions where a marker could originate either locally at the injury site or systemically as a general stress response.

For instance, in tracking large-artery atherosclerotic stroke, Xinwei He et al. observed climbing serum periostin levels in Longitudinal evaluation of serum periostin levels in patients after large-artery atherosclerotic stroke: A prospective observational study. However, because periostin is produced across multiple organ systems, it remains unclear whether these changes directly reflect localized brain damage or a broader systemic reaction.

Similarly, in Alzheimer's disease research, Masaya Matsuzaki et al. identified the enzymatic pathway behind a promising blood-based amyloid biomarker in ADAMTS4 is involved in the production of the Alzheimer disease amyloid biomarker APP669-711, yet noted that interpreting plasma concentrations is heavily complicated by uncertainty over whether the peptide originates from the brain or peripheral tissues.

This spatial blind spot also hampers amyotrophic lateral sclerosis (ALS) diagnostics. Laura Pasetto et al. argued in Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis that refining diagnostic tools requires distinguishing whether circulating extracellular vesicles (EVs) originate from the central nervous system or peripheral muscles.

Even in critical illness, as explored by Junru Wu et al. in Lipidomic signatures align with inflammatory patterns and outcomes in critical illness, circulating metabolite profiles fail to reveal the underlying source or destination of specific molecules, making it difficult to separate systemic metabolic failure from localized tissue-specific responses.

[Brain / Injury Site] ----> (Secreted Biomarker) ---\
                                                     \---> [Pooled Blood Sample] 
[Peripheral Tissues] ----> (Identical Biomarker) ----/     (Source Ambiguity)

Overlapping Biological Identities

Source ambiguity deepens when two distinct biological entities within the same organism produce identical chemical signatures.

Consider organ transplantation: in Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft, E. H. Liu et al. noted that tracking the recovery of a patient's native pancreatic beta cells is confounded because both the graft and the native tissue secrete the exact same chemical markers.

A parallel dilemma occurs during pregnancy, where maternal blood becomes a shared reservoir for the mother, the fetus, and the placenta. In Murine trophoblast-derived and pregnancy-associated exosome-enriched extracellular vesicle microRNAs: Implications for placenta driven effects on maternal physiology, Adrianne L. Stefanski et al. highlighted that without definitive attribution of serum-borne vesicles to the placenta rather than maternal tissues, researchers cannot confidently map direct placental signaling.

This challenge extends to prenatal exposures; a study on Metabolomics reveals effects of maternal smoking on endogenous metabolites from lipid metabolism in cord blood of newborns demonstrated that cord blood metabolites mirror maternal profiles, making it difficult to pinpoint which specific tissues are driving the observed systemic shifts without advanced tracing.

Cellular Heterogeneity within Complex Microenvironments

Even within a single localized fluid or tissue microenvironment, a biomarker may stem from multiple overlapping cell types, confounding whether a signal represents a host response, a pathogen, or a specific cellular actor.

In periodontal disease, G. Cimasoni showed in Alkaline Phosphatase Activity in Periodontal Disease that elevated alkaline phosphatase in gingival fluid could originate from subgingival bacteria, migrating leukocytes, or alveolar bone degradation. Without identifying the primary contributor, clinicians cannot tell if the marker indicates a host immune response or pathogen load.

Similarly, when evaluating allograft injury, Tej D. Azad et al. noted in Inflammatory macrophage–associated 3-gene signature predicts subclinical allograft injury and graft survival that interpreting gene expression signatures is complicated when the signals are shared across multiple cell types, such as macrophages and endothelial cells.

In oncology, the historical hunt for melanoma markers by G Agrup et al. in Demonstration of 3-methoxytyrosine in the urine of melanoma patients illustrated the classic challenge of determining whether an excreted metabolite originates exclusively from a specific tumor type or if other physiological pathways contribute. This is echoed in modern immunology by Zeyu Huang et al. in Extracellular vesicle-mediated communication between CD8+ cytotoxic T cells and tumor cells, who emphasized that the inability to distinguish between extracellular vesicles originating from malignant cells versus healthy tissue hinders their utility as precise diagnostic or therapeutic tools.

Compartmentalization and Fluid Dynamics

Biofluids are not uniform mixtures; they contain distinct fractions—such as free-floating molecules, microvesicles, and cells—that carry completely different biological meanings.

In Discordant Expression of Circulating microRNA from Cellular and Extracellular Sources, Ravi V. Shah et al. uncovered a massive discordance between microRNA levels in whole blood versus plasma, proving that cellular and extracellular fractions reflect entirely different physiological states and cannot be used interchangeably.

In acute injuries like ischemic stroke, Xin Gao et al. demonstrated in Neutrophil extracellular traps mediated by platelet microvesicles promote thrombosis and brain injury in acute ischemic stroke that signaling proteins are released simultaneously by circulating microvesicles and damaged local tissue, complicating the assessment of whether systemic or localized cellular responses drive secondary inflammation.

Furthermore, even within a single organ, fluid heterogeneity obscures internal communication maps. Tannia Gracia et al. showed in Urinary Exosomes Contain MicroRNAs Capable of Paracrine Modulation of Tubular Transporters in Kidney that urinary exosomes mediate complex paracrine signaling within different segments of the kidney, yet deconvoluting these specific internal origins from a heterogeneous fluid sample remains an open challenge.

How the Field Resolves Ambiguity

To transform these pooled biofluid signals into precise localized diagnostics, researchers are developing strategies to deconvolve cellular origins through enrichment, multi-omic profiling, and reference atlases.

Vesicle Enrichment and Lineage Tracing

Instead of analyzing bulk plasma, researchers isolate specific vesicle fractions to filter out background noise. For example, Arnab Datta et al. utilized quantitative proteomics on microvesicle-enriched plasma in Discovery of Prognostic Biomarker Candidates of Lacunar Infarction by Quantitative Proteomics of Microvesicles Enriched Plasma to isolate tissue-specific markers from systemic endothelial noise.

Similarly, a study on bone remodeling, Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation, highlighted the necessity of quantifying the precise proportional contribution of a single cell type (like osteoclasts) to the total systemic pool when multiple organ systems contribute.

Mapping the Extracellular RNA-ome

Expanding our understanding of what circulates in biofluids helps establish baseline tissue contributions. Jane E. Freedman et al. demonstrated in Diverse human extracellular RNAs are widely detected in human plasma that human plasma contains a highly diverse array of non-microRNA species (like piRNAs and snoRNAs), laying the groundwork for organ-specific transcript mapping.

Unified Reference Atlases

To systematically address the challenge of distinguishing tissue-specific vesicles from background blood cells, researchers are building comprehensive databases. Hongyan Lai et al. introduced exoRBase 2.0: an atlas of mRNA, lncRNA and circRNA in extracellular vesicles from human biofluids, which catalogs RNA signatures across various human biofluids to provide a unified platform for resolving the cellular and tissue origins of circulating extracellular vesicles.

Key Foundational Work

Alkaline Phosphatase Activity in Periodontal Disease (1971) — contributed 2 concept elements to this direction.
Demonstration of 3-methoxytyrosine in the urine of melanoma patients (1976) — contributed 1 concept elements to this direction.
History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 18 papers
  2. Version 1 · 2026-10-04 · 18 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_biomarker_source_ambiguity_94f098c5,
  title = {biomarker source ambiguity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/biomarker-source-ambiguity/rdr_94f098c517f5481d9b642c53e5da0c46},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 2, frozen text):

@misc{lacuna_biomarker_source_ambiguity_94f098c5_v2,
  title = {biomarker source ambiguity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/biomarker-source-ambiguity/rdr_94f098c517f5481d9b642c53e5da0c46/v/2},
  note = {Version 2, frozen 2026-10-04. Accessed 2026-11-22},
}

See something wrong? Report a mistake